Reviva Pharmaceuticals Holdings, Inc.
brilaroxazine
schizophrenia
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on brilaroxazine for schizophrenia is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“If successful, this initiative has the potential to meaningfully extend the commercial exclusivity of brilaroxazine and strengthen the Company’s ability to realize the full value of the program over time.”